Kringle Pharma, Inc.
Financial Summary for the Fiscal Year Ended September 2026 (Japanese GAAP) (Non-consolidated)
Net sales 442 million yen (YoY increase of 513.3%), operating loss 813 million yen, net loss 813 million yen. For fiscal 2027, net sales are forecast at 127 million yen with an expected operating loss of 1,773 million yen, indicating a substantial deficit. Future primary revenue sources are expected to include active pharmaceutical ingredient supply revenue and technology access fees from Clarice Biotherapeutics in the U.S., and upfront contract income for a vocal fold scar treatment in Japan. As a material event regarding the going concern assumption, issuance of new shares and share acquisition rights is being considered as fundraising measures and capital policy actions will be implemented.
Key Figures
- Net sales: 442 million yen
- Operating loss: -813,446 thousand yen
- Net loss attributable to owners of parent: -813,642 thousand yen
AI要約
Business Overview
Kringle Pharma, Inc., as a drug discovery venture focused on its key pipeline, reported a substantial increase in net sales to 442 million yen for the fiscal year ended September 2026, while recording operating, ordinary and net losses. The business consists of a single segment of pharmaceutical development, and clinical development activities progressed, including the start of an additional Phase III trial. Going forward, the company expects to stabilize revenues through API supply and technology access fee income in the U.S. market and contract upfront income for a vocal fold scar treatment in Japan. Issuance of new shares and share acquisition rights is planned as fundraising measures to stabilize cash flow.
Outlook and Capital Policy
Net sales for the fiscal year ending September 2027 are forecast to decline significantly to 127 million yen; however, ongoing revenue streams such as technology access fees and milestone income are assumed. Research and development expenses are expected to increase, with projected operating loss of 1,773 million yen, ordinary loss of 1,773 million yen, and net loss of 1,775 million yen. As part of its capital policy, the company has resolved to issue new shares through a third-party allotment and to issue share acquisition rights, with proceeds to be used for U.S. Phase III trial preparation costs, establishment of API manufacturing capabilities, domestic API manufacturing and working capital.
Kringle Pharma, Inc.
Company overview · Stock price · Financial data · All IR
